Intelligent Bio Solutions Inc. (NASDAQ:INBS) Short Interest Up 147.3% in June

Intelligent Bio Solutions Inc. (NASDAQ:INBS) saw a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 90,000 shares, a growth of 147.3% from the May 31st total of 36,400 shares. Currently, 2.9% of the company’s shares are sold short. Based on an average trading volume of 61,400 shares, the days-to-cover ratio is currently 1.5 days.

Intelligent Bio Solutions Trading Up 2.7 %

NASDAQ:INBS traded up $0.05 during trading hours on Friday, hitting $1.92. The company had a trading volume of 87,347 shares, compared to its average volume of 48,560. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.02 and a quick ratio of 1.87. The stock has a 50-day moving average price of $2.29 and a 200 day moving average price of $3.39. The company has a market capitalization of $5.99 million, a PE ratio of -0.05 and a beta of 4.75. Intelligent Bio Solutions has a 52 week low of $1.76 and a 52 week high of $39.48.

Intelligent Bio Solutions (NASDAQ:INBS) last announced its earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share for the quarter. Intelligent Bio Solutions had a negative net margin of 354.86% and a negative return on equity of 210.36%. The company had revenue of $0.82 million for the quarter. On average, equities research analysts predict that Intelligent Bio Solutions will post -3.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Intelligent Bio Solutions

An institutional investor recently bought a new position in Intelligent Bio Solutions stock. CVI Holdings LLC bought a new stake in shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 108,250 shares of the company’s stock, valued at approximately $457,000. Intelligent Bio Solutions comprises 0.4% of CVI Holdings LLC’s investment portfolio, making the stock its 27th largest position. CVI Holdings LLC owned approximately 3.81% of Intelligent Bio Solutions as of its most recent SEC filing. Institutional investors own 32.97% of the company’s stock.

About Intelligent Bio Solutions

Intelligent Bio Solutions Inc, a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.